Michael Møller

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Tina Green, Ken H. Young, Carlo Visco et al. · Journal of Clinical Oncology · 2012 · 677 citations · Full text

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 671 citations · Full text

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 383 citations · Full text

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Carlo Visco, Y Li, Zijun Y. Xu‐Monette et al. · Leukemia · 2012 · 354 citations

Hematological Malignancy, Lymphoid Neoplasia, Engineering +14

Malignant Transformation of Neurofibromas in Neurofibromatosis 1 Is Associated with CDKN2A/p16 Inactivation

G. Petur Nielsen, Anat Stemmer‐Rachamimov, Yasushi Ino et al. · American Journal Of Pathology · 1999 · 264 citations · Full text

Neuro-oncology, Cdkn2a/p16 Inactivation, Fibrosis +11